Esperion Therapeutics Completes $22.75 M Series A Financing
- Details
- Category: Pfizer

Lundbeck expands geographical rights for Circadin®
- Details
- Category: Lundbeck

AstraZeneca Submits sNDA for SYMBICORT® for COPD Treatment
- Details
- Category: AstraZeneca

Novo Nordisk will donate a licence to its small molecule compound library
- Details
- Category: Novo Nordisk

Follicular lymphoma: EU approval for Zevalin® as First-Line Consolidation Treatment
- Details
- Category: Bayer

Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.12 for the first quarter of 2008, an increase of 4 percent compared to $1.08 for the first quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, decreased 4 percent to $1,218 million in the first quarter of 2008 compared to $1,270 million in the first quarter of 2007.
Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology
- Details
- Category: Pfizer

More Pharma News ...
- Two Merck Medicines Recommended for Approval in the European Union
- GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million
- AstraZeneca PLC First Quarter Results 2008
- Genzyme Reports Strong First-Quarter Growth
- Novartis reports higher sales and earnings in first quarter of 2008
- Novartis announces 20% average reduction in price of malaria drug Coartem®
- The Medicines Company Reports First Quarter 2008 Financial Results